Chemokine CXCL8 and its receptors as markers of colorectal cancer
- Authors: Bogomolova I.A.1, Antoneeva I.I.2,3, Dolgova D.R.2, Abakumova T.V.2, Gening T.P.2
-
Affiliations:
- Federal Scientific and Clinical Center for Medical Radiology and Oncology of the Federal Medical and Biological Agency of Russia
- Ulyanovsk State University
- Regional Clinical Oncology Dispensary
- Issue: Vol 105, No 3 (2024)
- Pages: 424-432
- Section: Theoretical and clinical medicine
- URL: https://bakhtiniada.ru/kazanmedj/article/view/257026
- DOI: https://doi.org/10.17816/KMJ609502
- ID: 257026
Cite item
Open Access
Access granted
Subscription Access
Abstract
BACKGROUND: The chemokine CXCL8 and its receptor are involved in the activation and transport of inflammatory mediators and regulate the proliferation and renewal of cancer stem cells in colon cancer. It is believed that CXC signaling may be associated with poor prognosis in colorectal cancer.
AIM: To study the possibilities of using CXCL8-CXCR1/2 pathway indicators as markers in colorectal cancer.
MATERIAL AND METHODS: Isolation of ribonucleic acid (RNA) from histological sections of tumors obtained intraoperatively from 59 patients diagnosed with colorectal cancer was carried out using magnetic particles, and quantitative polymerase chain reaction in real time was performed. Calculation of the normalized expression of the CXCL8 and CXCR1 genes relative to the referee gene was done using special software. Statistical data processing was performed using Statistica 3.0, BioStat v. 7.1 programs. Comparisons of characteristics were performed using the Mann–Whitney U test. Cox and Kaplan–Meier criteria were used to analyze overall and disease-free survival.
RESULTS: The expression of CXCL8 in intestinal adenocarcinoma cells with low differentiation [Me (Q1–Q3) — 8.770 (1.127–1.114)] was significantly higher than in the groups of moderately and well differentiated tumors (p=0.004 and p=0.012, respectively); and in tumor tissue refractory to chemotherapy, it was significantly higher [4.374 (2.052–7.045)] compared to resistant [2.200 (1.388–5.037); p=0.008] and sensitive [1.624 (0.739–2.586); p=0.042]. The level of CXCR1 messenger RNA in tumor tissue was increased in the presence of BRAF mutation [3.645 (0.801–1.090); p=0.009] and low tumor differentiation [6.965 (3.938–12.225); p=0.002], as well as in tumor tissue refractory to FOLFOX/XELOX chemotherapy [46.224 (27.580–83.570); p=0.0009].
CONCLUSION: Expression of components of the CXCL8-CXCR1/2 signaling pathway in tumor tissue may be a marker of sensitivity to FOLFOX/XELOX chemotherapy in colorectal cancer.
Full Text
##article.viewOnOriginalSite##About the authors
Irina A. Bogomolova
Federal Scientific and Clinical Center for Medical Radiology and Oncology of the Federal Medical and Biological Agency of Russia
Author for correspondence.
Email: 73bogomolova@gmail.com
ORCID iD: 0000-0003-3331-8632
M.D., Head of Depart., Depart. of Antitumor Drug Therapy
Russian Federation, DimitrovgradInna I. Antoneeva
Ulyanovsk State University; Regional Clinical Oncology Dispensary
Email: aii72@mail.ru
ORCID iD: 0000-0002-1525-2070
M.D., D. Sci. (Med.), Prof., Depart. of Oncology and Radiation Diagnostics; Head of Depart., Depart. of Gynecology
Russian Federation, Ulyanovsk; UlyanovskDinara R. Dolgova
Ulyanovsk State University
Email: dolgova.dinara@yandex.ru
ORCID iD: 0000-0001-5475-7031
Cand. Sci. (Biol.), Assoc. Prof., Depart. of Physiology and Pathophysiology, Director of the Scientific Research Medical and Biological Center
Russian Federation, UlyanovskTatyana V. Abakumova
Ulyanovsk State University
Email: taty-abakumova@yandex.ru
ORCID iD: 0000-0001-7559-5246
D. Sci. (Biol.), Prof., Depart. of Physiology and Pathophysiology
Russian Federation, UlyanovskTatyana P. Gening
Ulyanovsk State University
Email: Naum-53@yandex.ru
ORCID iD: 0000-0002-5117-1382
D. Sci. (Biol.), Prof., Head of Depart., Depart. of Physiology and Pathophysiology
Russian Federation, UlyanovskReferences
- Matsushima K, Yang D, Oppenheim JJ. Interleukin-8: An evolving chemokine. Cytokine. 2022;153:155828. doi: 10.1016/j.cyto.2022.155828.
- Jia SN, Han YB, Yang R, Yang ZC. Chemokines in colon cancer progression. Semin Cancer Biol. 2022;86(3):400–407. doi: 10.1016/j.semcancer.2022.02.007.
- Chen W, Huang J, Xiong J, Fu P, Chen C, Liu Y, Li Z, Jie Z, Cao Y. Identification of a tumor microenvironment-related gene signature indicative of disease prognosis and treatment response in colon cancer. Oxid Med Cell Longev. 2021;2021:6290261. doi: 10.1155/2021/6290261.
- Łukaszewicz-Zając M, Pączek S, Mroczko P, Kulczyńska-Przybik A. The significance of CXCL1 and CXCL8 as well as their specific receptors in colorectal cancer. Cancer Manag Res. 2020;12:8435–8443. doi: 10.2147/CMAR.S267176.
- Xiong X, Liao X, Qiu S, Xu H, Zhang S, Wang S, Ai J, Yang L. CXCL8 in tumor biology and its implications for clinical translation. Front Mol Biosci. 2022;9:723846. doi: 10.3389/fmolb.2022.723846.
- Thiel G, Ulrich M, Mukaida N, Rössler OG. Resveratrol stimulation induces interleukin-8 gene transcription via NF-κB. Pharmacol Res. 2018;134:238–245. doi: 10.1016/j.phrs.2018.07.003.
- Liu Q, Li A, Tian Y, Wu JD, Liu Y, Li T, Chen Y, Han X, Wu K. The CXCL8-CXCR1/2 pathways in cancer. Cytokine Growth Factor Rev. 2016;31:61–71. doi: 10.1016/j.cytogfr.2016.08.002.
- Biasci D, Smoragiewicz M, Connell CM, Wang Z, Gao Y, Thaventhiran JED, Basu B, Magiera L, Johnson TI, Bax L, Gopinathan A, Isherwood C, Gallagher FA, Pawula M, Hudecova I, Gale D, Rosenfeld N, Barmpounakis P, Popa EC, Brais R, Godfrey E, Mir F, Richards FM, Fearon DT, Janowitz T, Jodrell DI. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proc Natl Acad Sci USA. 2020;117(46):28960–28970. doi: 10.1073/pnas.2013644117.
- Stone MJ, Hayward JA, Huang C, Huma ZЕ, Sanchez J. Mechanisms of regulation of the chemokine-receptor network. Int J Mol Sci. 2017;18(2):342. doi: 10.3390/ijms18020342.
- Borroni EM, Savino B, Bonecchi R, Locati M. Chemokines sound the alarmin: The role of atypical chemokine in inflammation and cancer. Semin Immunol. 2018;38:63–71. doi: 10.1016/j.smim.2018.10.005.
- Huynh C, Dingemanse J, Meyer Zu Schwabedissen HE, Sidharta PN. Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions. Pharmacol Res. 2020;161:105092. doi: 10.1016/j.phrs.2020.105092.
- Harcken C, Kuzmich D, Cook B, Mao C, Disalvo D, Razavi H, Swinamer A, Liu P, Zhang Q, Kukulka A, Skow D, Patel M, Patel M, Fletcher K, Sherry T, Joseph D, Smith D, Canfield M, Souza D, Bogdanffy M, Berg K, Brown M. Identification of novel azaindazole CCR1 antagonist clinical candidates. Bioorg Med Chem Lett. 2019;29(3):441–448. doi: 10.1016/j.bmcl.2018.12.024.
- Cheng Y, Ma XL, Wei YQ, Wei XW. Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases. Biochim Biophys Acta Rev Cancer. 2019;1871(2):289–312. doi: 10.1016/j.bbcan.2019.01.005.
- Ha H, Debnath B, Neamati N. Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases. Theranostics. 2017;7(6):1543–1588. doi: 10.7150/thno.15625.
- Molczyk C, Singh RK. CXCR1: A cancer stem cell marker and therapeutic target in solid tumors. Biomedicines. 2023;11(2):576. doi: 10.3390/biomedicines11020576.
- Oladipo O, Conlon S, O'Grady A, Purcell C, Wilson C, Maxwell PJ, Johnston PG, Stevenson M, Kay EW, Wilson RH, Waugh DJ. The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue. Br J Cancer. 2011;104(3):480–487. doi: 10.1038/sj.bjc.6606055.
- Shawki S, Ashburn J, Signs SA, Huang E. Colon cancer: Inflammation-associated cancer. Surg Oncol Clin N Am. 2018;27(2):269–287. doi: 10.1016/j.soc.2017.11.003.
- Fisher RC, Bellamkonda K, Molina LA, Xiang S, Liska D, Sarvestani SK, Chakrabarti S, Berg A, Jorgensen ML, Hatala D, Chen S, Aiello A, Appelman HD, Scott EW, Huang EH. Disrupting inflammation-associated CXCL8-CXCR1 signaling inhibits tumorigenicity initiated by sporadic- and colitis-colon cancer stem cells. Neoplasia. 2019;21:269–281. doi: 10.1016/j.neo.2018.12.007.
- Zhu Y, Yang S, Zhao N, Liu C, Zhang F, Guo Y, Liu H. CXCL8 chemokine in ulcerative colitis. Biomed Pharmacother. 2021;138:111427. doi: 10.1016/j.biopha.2021.111427
- Xue MQ, Liu J, Sang JF, Su L, Yao YZ. Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer. Oncotarget. 2017;8(30):48930–48937. doi: 10.18632/oncotarget.16893.
- Le Rolle AF, Chiu TK, Fara M, Shia J, Zeng Z, Weiser MR, Paty PB, Chiu VK. The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblasts. J Transl Med. 2015;13:199. doi: 10.1186/s12967-015-0555-4.
Supplementary files
